Panacea Biotec Ltd. has entered into a broad collaboration with Bionpharma Inc for certain complex generic products. The deal is part of Panacea’s drive to expand its US product portfolio as it targets global player status in technology-based specialty generics and, more urgently, seeks to return to profit. The tie-up is the Indian firm’s second with Bionpharma and involves R&D, manufacturing and marketing seven ANDAs, mainly in the organ transplant immunosuppressant field.
Panacea, an Indian biotech firm and one of the country’s biggest vaccine-makers, suffered a financial body blow in 2011 when...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
